Early impact of the Inflation Reduction Act on small molecule vs biologic post-approval oncology trials
Hanke Zheng1, Julie A Patterson1, Jonathan D Campbell1
1Research Department, National Pharmaceutical Council, Washington, DC 20006, United States.
Introduction:
Under the Inflation Reduction Act (IRA), small molecule drugs are subject to a shorter timeline toward eligibility for selection to the Drug Price Negotiation Program (DPNP) than biologics (7 vs 11 years post-approval), raising concerns about incentives for post-approval clinical development.
Methods:
Using Citeline's Trialtrove database (7/2014-8/2024), this longitudinal study explored the impact of IRA's passage on industry-sponsored, post-approval phase I-III clinical trials in small molecule vs biologic oncology drugs, excluding vaccine-related trials. We used a difference-in-difference design to explore the impact of the IRA's differential DPNP timeline on small molecule trials in oncology by comparing changes in the number of newly initiated post-approval trials in small molecule drugs after the IRA (first difference) with changes in biological trials (second difference).
Results:
The monthly average of small molecule and biologic trials dropped by 45.3% (P < .01) and 32.5% (P < .01) post-IRA, respectively. Compared with biologics, small molecules were associated with an additional decrease of 4.5 trials/month (-4.5, 95% CI, -7.1 to -1.9; P < .01) after the IRA's passage.
Conclusion:
This finding supports hypotheses that the IRA's differential timelines toward DPNP eligibility for the 2 molecule types may disproportionately disincentivize post-approval research in small molecule drugs.
More Related Videos
Related Concept Videos
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Clinical Trials: Overview
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Factors Affecting Drug Response: Overview
Bioequivalence: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...


